US 10973830
Substituted quinoxaline DNA-PK inhibitors
granted A61KA61K31/506A61K31/5377
Quick answer
US patent 10973830 (Substituted quinoxaline DNA-PK inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/5386, A61P